Windtree Therapeutics Inc (NASDAQ:WINT) has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 of 2022.

• The 20-subject Phase 2 trial is designed to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in mechanically ventilated patients due to this COVID-19 associated acute lung injury. 
• Functional changes in gas exchange and lung compliance are also being measured.
• Lucinactant is a synthetic surfactant structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 (sinapultide). 
• This 21-amino acid peptide is designed to imitate the human surfactant protein B (SP-B). S
• Price Action: WINT shares are up 21.20% at $1.37 during the market session on the last check Tuesday.